Literature DB >> 32156722

Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition.

Phuong L Mai1, Sharon R Sand2, Neiladri Saha3, Mauricio Oberti3, Tom Dolafi3, Lisa DiGianni4, Elizabeth J Root4, Xianhua Kong5, Renee C Bremer6, Karina M Santiago7, Jasmina Bojadzieva5, Derek Barley8, Ana Novokmet9, Karen A Ketchum3, Ngoc Nguyen3, Shine Jacob3, Kim E Nichols10, Christian P Kratz11, Joshua D Schiffman12, D Gareth Evans8, Maria Isabel Achatz13, Louise C Strong6, Judy E Garber5, Sweta A Ladwa3, David Malkin9, Jeffrey N Weitzel14.   

Abstract

BACKGROUND: The success of multisite collaborative research relies on effective data collection, harmonization, and aggregation strategies. Data Coordination Centers (DCC) serve to facilitate the implementation of these strategies. The utility of a DCC can be particularly relevant for research on rare diseases where collaboration from multiple sites to amass large aggregate datasets is essential. However, approaches to building a DCC have been scarcely documented.
METHODS: The Li-Fraumeni Exploration (LiFE) Consortium's DCC was created using multiple open source packages, including LAM/G Application (Linux, Apache, MySQL, Grails), Extraction-Transformation-Loading (ETL) Pentaho Data Integration Tool, and the Saiku-Mondrian client. This document serves as a resource for building a rare disease DCC for multi-institutional collaborative research.
RESULTS: The primary scientific and technological objective to create an online central repository into which data from all participating sites could be deposited, harmonized, aggregated, disseminated, and analyzed was completed. The cohort now include 2,193 participants from six contributing sites, including 1,354 individuals from families with a pathogenic or likely variant in TP53. Data on cancer diagnoses are also available. Challenges and lessons learned are summarized.
CONCLUSIONS: The methods leveraged mitigate challenges associated with successfully developing a DCC's technical infrastructure, data harmonization efforts, communications, and software development and applications. IMPACT: These methods can serve as a framework in establishing other collaborative research efforts. Data from the consortium will serve as a great resource for collaborative research to improve knowledge on, and the ability to care for, individuals and families with Li-Fraumeni syndrome. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32156722      PMCID: PMC7196512          DOI: 10.1158/1055-9965.EPI-19-1113

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  30 in total

1.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Authors:  Mandy L Ballinger; Ana Best; Phuong L Mai; Payal P Khincha; Jennifer T Loud; June A Peters; Maria Isabel Achatz; Rubens Chojniak; Alexandre Balieiro da Costa; Karina Miranda Santiago; Judy Garber; Allison F O'Neill; Rosalind A Eeles; D Gareth Evans; Eveline Bleiker; Gabe S Sonke; Marielle Ruijs; Claudette Loo; Joshua Schiffman; Anne Naumer; Wendy Kohlmann; Louise C Strong; Jasmina Bojadzieva; David Malkin; Surya P Rednam; Elena M Stoffel; Erika Koeppe; Jeffrey N Weitzel; Thomas P Slavin; Bita Nehoray; Mark Robson; Michael Walsh; Lorenzo Manelli; Anita Villani; David M Thomas; Sharon A Savage
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

2.  Informatics and data quality at collaborative multicenter Breast and Colon Cancer Family Registries.

Authors:  Peter B McGarvey; Sweta Ladwa; Mauricio Oberti; Anca Dana Dragomir; Erin K Hedlund; David Michael Tanenbaum; Baris E Suzek; Subha Madhavan
Journal:  J Am Med Inform Assoc       Date:  2012-02-09       Impact factor: 4.497

3.  Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.

Authors:  E D Lustbader; W R Williams; M L Bondy; S Strom; L C Strong
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

4.  2009 version of the Chompret criteria for Li Fraumeni syndrome.

Authors:  Julie Tinat; Gaelle Bougeard; Stéphanie Baert-Desurmont; Stéphanie Vasseur; Cosette Martin; Emilie Bouvignies; Olivier Caron; Brigitte Bressac-de Paillerets; Pascaline Berthet; Catherine Dugast; Catherine Bonaïti-Pellié; Dominique Stoppa-Lyonnet; Thierry Frébourg
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

5.  Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.

Authors:  Serena Masciari; Deborah A Dillon; Michelle Rath; Mark Robson; Jeffrey N Weitzel; Judith Balmana; Stephen B Gruber; James M Ford; David Euhus; Alexandra Lebensohn; Melinda Telli; Stephen M Pochebit; Georgios Lypas; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2012-03-04       Impact factor: 4.872

6.  Coordinating centers in cancer epidemiology research: the Asia Cohort Consortium coordinating center.

Authors:  Betsy Rolland; Briana R Smith; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-29       Impact factor: 4.254

7.  Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.

Authors:  Phuong L Mai; David Malkin; Judy E Garber; Joshua D Schiffman; Jeffrey N Weitzel; Louise C Strong; Oliver Wyss; Luana Locke; Von Means; Maria Isabel Achatz; Pierre Hainaut; Thierry Frebourg; D Gareth Evans; Eveline Bleiker; Andrea Patenaude; Katherine Schneider; Benjamin Wilfond; June A Peters; Paul M Hwang; James Ford; Uri Tabori; Simona Ognjanovic; Phillip A Dennis; Ingrid M Wentzensen; Mark H Greene; Joseph F Fraumeni; Sharon A Savage
Journal:  Cancer Genet       Date:  2012-08-29

8.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.

Authors:  K E Nichols; D Malkin; J E Garber; J F Fraumeni; F P Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-02       Impact factor: 4.254

9.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

10.  Routine TP53 testing for breast cancer under age 30: ready for prime time?

Authors:  Jeanna M McCuaig; Susan R Armel; Ana Novokmet; Ophira M Ginsburg; Rochelle Demsky; Steven A Narod; David Malkin
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

View more
  3 in total

1.  Inherited TP53 Variants and Risk of Prostate Cancer.

Authors:  Kara N Maxwell; Heather H Cheng; Jacquelyn Powers; Roman Gulati; Elisa M Ledet; Casey Morrison; Anh Le; Ryan Hausler; Jill Stopfer; Sophie Hyman; Wendy Kohlmann; Anne Naumer; Jennie Vagher; Samantha E Greenberg; Lorraine Naylor; Mercy Laurino; Eric Q Konnick; Brian H Shirts; Saud H AlDubayan; Eliezer M Van Allen; Bastien Nguyen; Joseph Vijai; Wassim Abida; Maria I Carlo; Marianne Dubard-Gault; Daniel J Lee; Luke D Maese; Diana Mandelker; Bruce Montgomery; Michael J Morris; Piper Nicolosi; Robert L Nussbaum; Lauren E Schwartz; Zsofia Stadler; Judy E Garber; Kenneth Offit; Joshua D Schiffman; Peter S Nelson; Oliver Sartor; Michael F Walsh; Colin C Pritchard
Journal:  Eur Urol       Date:  2021-12-01       Impact factor: 20.096

2.  Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body.

Authors:  Allison Werner-Lin; Rowan Forbes Shepherd; Jennifer L Young; Catherine Wilsnack; Shana L Merrill; Mark H Greene; Payal P Khincha
Journal:  Soc Sci Med       Date:  2022-03-17       Impact factor: 5.379

3.  Lessons learned and recommendations for data coordination in collaborative research: The CSER consortium experience.

Authors:  Kathleen D Muenzen; Laura M Amendola; Tia L Kauffman; Kathleen F Mittendorf; Jeannette T Bensen; Flavia Chen; Richard Green; Bradford C Powell; Mark Kvale; Frank Angelo; Laura Farnan; Stephanie M Fullerton; Jill O Robinson; Tianran Li; Priyanka Murali; James M J Lawlor; Jeffrey Ou; Lucia A Hindorff; Gail P Jarvik; David R Crosslin
Journal:  HGG Adv       Date:  2022-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.